Skip to main content
Premium Trial:

Request an Annual Quote

Fluorotechnics' Q1 Revenues Drop to $224K

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian fluorescence and protein detection technologies firm Fluorotechnics last week reported revenues from customers for the first quarter of A$204,346 (US$224,006), down nearly nine-fold from A$1.8 million a year ago.

The company, which is in the middle of a turnaround effort, also reported net operating cash flows came in at a loss of A$273,609 for the three months ended March 31, compared to a loss of A$1.5 million a year ago.

R&D costs were sliced to A$20,813 from A$254,80,6 and SG&A costs shriveled to A$7,667 from A$353,608 a year ago.

As part of its effort to stay afloat, Fluorotechnics sold its US subsidiary Gel Company for $150,000 in October, and its gel and High Performance Electrophoresis, or HPE, Tower technology in December.

In a letter accompanying the release of its Q1 earnings results, Ian Gilmour, company secretary, said that Fluorotechnics continues to scale back its operations and sell off assets, and the company's ongoing cash burn has been "significantly reduced."

Fluorotechnics is evaluating new investment opportunities, Gilmour added.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.